HELSINKI, Finland, July 5, 2010 /PRNewswire/ -- Standard methods in pharmaceutical production often reach their technological limits - be it wet granulation, roller compaction or direct compression. The Finnish company Atacama Labs - http://www.atacamalabs.com - with its proprietary pneumatic dry granulation technology extends this limit successfully and provides free flowing granules of most any API. The so-called PDG technology helps galenic developers in offering clearly enhanced solutions for their development projects.

The PDG granulate offers a host of advantages versus today's granulate, in that it is both flowable and compactible and improves disintegration and dissolution, among others. Furthermore, the tablets can be furnished with a very high drug load (70-95%), decreasing tablet size to ameliorate patient compliance and making it optimal for fix combinations.

Furthermore, the technological advantages not only help in galenic development, but even more so in the later industrial production process. Significant cost reduction of up to 30%, a simple process with 3 steps with continuous production and a high input/output ratio are hallmarks of Atacama Labs' innovative production method. Scale-up from lab scale is no longer to be considered an issue.

Steffen Mittwich, CEO of Atacama Labs, gets to the point: With our PDG process we are able to provide a simple, cost effective and highly reliable production method which also facilitates new pharmaceutical developments and helps to overcome existing galenic development hurdles.

Brand new scientific study results have now been published regarding traditionally difficult-to-handle substances: Paracetamol, Metformin, microcristalline cellulose and Ibuprofen. The results are proving that these products can be transformed via dry granulation into freely flowing granulate with excellent compactibility properties. The resulting tablets show satisfactory hardness and friability profiles with no capping and excellent disintegration and dissolution data. (see also http://www.atacamalabs.com/publications-posters)

With its innovative PDG technology, the company from Helsinki succeeds in improving life cycle management options, providing new product and production possibilities to pharmaceutical companies and oral dosage forms with high drug load in optimal quality.

Information: Steffen Mittwich Atacama Labs Oy Fredrikinkatu 61 6th floor 00100 Helsinki Finnland, Tel. +41-79-3693410 E-Mail: info@atacamalabs.com Web: http://www.atacamalabs.com

SOURCE: Atacama Labs Oy

CONTACT: Information: Steffen Mittwich, Atacama Labs Oy, Tel.+41-79-3693410, E-Mail: info@atacamalabs.com